The UK and US have secured a important bilateral deal that will preserve no levies on UK medicine exports being sold in the American market.
The Terms of the Accord
In exchange for the tariff guarantee, the UK has committed to increase expenditure on medicines through the public health system. This commitment secures that import taxes on these key products will be held at zero for a timeframe of three years.
This development follows previous warnings to hike duties on branded drug imports, with increases mentioned reaching 100%.
"This arrangement with the UK bolsters the international landscape for cutting-edge drugs and introduces much-needed balance to U.S.–U.K. medicine commerce," an announcement noted.
Commercial Significance
Drugs are one of the UK's biggest exports to the America, which is easily the primary market for large UK drugmakers.
Export figures reveal that in the 12 months leading up to last September, the UK sold pharmaceutical products totaling £11.1bn to the US. This value represented 17.4% of total UK exports in that span.
"This deal secures work, stimulates funding and paves the way for the UK to become a worldwide center for medical research," the Business and Trade Secretary commented.
Key UK Commitments
The pact includes several specific pledges from the UK:
- Higher Cost Ceiling: The UK will lift the price threshold at which it deems new medicines to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a goal to double total NHS spending on treatments from 0.3 percent of GDP to 0.6% over the coming ten years.
- Rebate Cap: The percentage manufacturers must refund to the NHS to stay within budget will be limited at fifteen percent. Last year, refunds topped 20%.
Broader Context
The pact follows a protracted row between the pharmaceutical industry and the ministers over drug pricing and NHS adoption.
The disagreement were exacerbated by claims that US customers were charged several times more for the identical medicines than patients in the Britain and the EU.
Over the last 18 months, several significant pharmaceutical investments in the UK have been halted or scrapped, while major investments have been announced toward US facilities.
One official acknowledged that the NHS needed to increase expenditure on medicines, noting that its budget allocation on drugs had shrunk as a proportion of its total funding over the past decade.
